Compare Davita Inc (DVA) vs US Bancorp (USB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Davita Inc vs US Bancorp — how do they compare? Davita Inc trades at $175.04 (market cap $11.29B), while US Bancorp trades at $57.07 (market cap $88.86B). The key difference: US Bancorp is far larger — about 7.9× Davita Inc's market cap, and US Bancorp pays a 3.79% dividend while Davita Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Davita Inc for 113 Days and US Bancorp for 97 Days on average.
| DVA | USB | |
|---|---|---|
Market Cap | $11.29B | $88.86B |
Volume | 582,204 | 8,869,993 |
Sector | Health | Financials |
52-Week High | $240.96 | $65.42 |
52-Week Low | $103.87 | $45.28 |
Typical Hold Time | 113 Days | 97 Days |
Enterprise Value | $24.01B | $118.35B |
Dividend Yield | — | 3.79% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $176.78, down 2.01% today, showing technical bearish signals with price near key support at $175. Fundamentally, the company demonstrates solid earnings performance with three consecutive quarterly beats and attractive valuation metrics including a P/E of 14.98 and P/S of 0.88. Recent expansion of value-based care partnerships with Humana positions the company for continued growth in kidney care services.
The stock presents a compelling value opportunity with analyst consensus target of $235.67 offering 33% upside potential, though investors face risks from regulatory pressures and narrowing profit margins. Warren Buffett's significant ownership (45%) and institutional buying activity provide confidence, but the bearish technical outlook and mixed analyst ratings (43% Buy, 52% Hold) suggest cautious optimism is warranted.
U.S. Bancorp (USB) trades at $56.17, down 1.95% with bearish technical signals but strong fundamentals including consistent earnings beats and a 27.61% net margin. The stock offers a $2.16 annual dividend yield with recent 3.8% increase. Analyst consensus is bullish with $69.94 price target despite near-term technical weakness.
USB presents a value opportunity with attractive P/E of 11.38 and strong profitability metrics, though investors face interest rate sensitivity and regulatory uncertainty risks. The bank's solid earnings track record and dividend growth support long-term investment case despite current bearish technical indicators.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →About US Bancorp
As a diversified financial-services provider, U.S. Bancorp is one of the nation's largest regional banks, with branches in well over 20 states, primarily in the Western and Midwestern United States. The bank offers many services, including retail banking, commercial banking, trust and wealth services, credit cards, mortgages, and other payments capabilities.
Read more on USB →
